BSX icon

Boston Scientific

104.49 USD
-0.87
0.83%
At close Feb 21, 4:00 PM EST
After hours
104.49
+0.00
0.00%
1 day
-0.83%
5 days
-1.52%
1 month
3.55%
3 months
14.20%
6 months
32.58%
Year to date
16.91%
1 year
58.92%
5 years
145.17%
10 years
540.65%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 53,000

0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 13 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

130% more first-time investments, than exits

New positions opened: 193 | Existing positions closed: 84

28% more repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 462

9% more funds holding in top 10

Funds holding in top 10: 35 [Q3] → 38 (+3) [Q4]

7% more capital invested

Capital invested by funds: $111B [Q3] → $120B (+$8.18B) [Q4]

4% more funds holding

Funds holding: 1,369 [Q3] → 1,423 (+54) [Q4]

0.04% more ownership

Funds ownership: 90.2% [Q3] → 90.24% (+0.04%) [Q4]

13% less call options, than puts

Call options by funds: $797M | Put options by funds: $912M

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$101
3%
downside
Avg. target
$116
11%
upside
High target
$130
24%
upside

13 analyst ratings

13 positive
100%
neutral
0%
negative
0%
Stifel
Rick Wise
64% 1-year accuracy
21 / 33 met price target
15%upside
$120
Buy
Maintained
10 Feb 2025
Barclays
Matt Miksic
72% 1-year accuracy
28 / 39 met price target
13%upside
$118
Overweight
Maintained
10 Feb 2025
UBS
Danielle Antalffy
69% 1-year accuracy
9 / 13 met price target
24%upside
$130
Buy
Maintained
7 Feb 2025
Raymond James
Jayson Bedford
80% 1-year accuracy
20 / 25 met price target
17%upside
$122
Strong Buy
Maintained
6 Feb 2025
RBC Capital
Shagun Singh
63% 1-year accuracy
44 / 70 met price target
11%upside
$116
Outperform
Maintained
6 Feb 2025

Financial journalist opinion

Based on 27 articles about BSX published over the past 30 days

Neutral
PRNewsWire
10 hours ago
Boston Scientific announces pricing of €1.5 billion of senior notes
MARLBOROUGH, Mass. , Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.
Boston Scientific announces pricing of €1.5 billion of senior notes
Positive
Zacks Investment Research
1 day ago
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
Neutral
PRNewsWire
2 days ago
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
MARLBOROUGH, Mass. , Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
Positive
Zacks Investment Research
4 days ago
PBH or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
PBH or BSX: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
1 week ago
EMEA Expansion to Support BSX Stock Amid Fierce Competition
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
Positive
Zacks Investment Research
1 week ago
5 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility
Invest in stocks of EAT, BFST, AZEK, CLS and BSX to tap their high efficiency levels.
5 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility
Positive
Forbes
1 week ago
What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.
What's Behind The 130% Rise In BSX Stock?
Neutral
Zacks Investment Research
1 week ago
The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific
The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific are included in this Analyst Blog.
The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific
Positive
Zacks Investment Research
1 week ago
Best Momentum Stocks to Buy for February 10th
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
Best Momentum Stocks to Buy for February 10th
Positive
Zacks Investment Research
1 week ago
5 Momentum Stocks to Buy for February Amid Volatility
These five stocks have strong momentum for February. These are: APH, BSX, NLY, PNFP, FHN.
5 Momentum Stocks to Buy for February Amid Volatility
Charts implemented using Lightweight Charts™